Ratings Celltrion, Inc.

Equities

A068270

KR7068270008

End-of-day quote Korea S.E. 23:00:00 18/06/2024 BST 5-day change 1st Jan Change
183,400 KRW +2.40% Intraday chart for Celltrion, Inc. -2.24% -8.98%

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • With an expected P/E ratio at 72.76 and 34.81 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • Based on current prices, the company has particularly high valuation levels.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
-8.98% 26.69B
C
+34.01% 51.07B
B-
+33.84% 38.86B
A
-8.02% 38.78B
B
+12.56% 26.35B
B-
-19.62% 19.46B
B
+39.18% 13.58B
B+
+31.47% 12.46B
C+
-3.40% 11.75B
B+
-11.25% 10.81B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes